General
Preferred name
PIMAVANSERIN
Synonyms
ACP-103 ()
ACP-103 tartrate ()
Nuplazid ()
ACP 103 ()
PIMAVANSERIN TARTRATE ()
PIMAVANSERINA ()
PIMAVANSERINE ()
P&D ID
PD008625
CAS
706782-28-7
868855-07-6
706779-91-1
Tags
available
drug
drug candidate
Approved by
FDA
First approval
2016
Drug indication
Alzheimer disease
Psychosis
Parkinson disease
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Pimavanserin is an inverse agonist of the serotonin 5-HT2A receptor . Pharmaceutical formulations contain pimavanserin tartrate (PubChem CID 67017013) . (GtoPdb)
PRICE 29
DESCRIPTION Pimavanserin is a selective inverse agonist of the 5-HT2A receptor with pIC50 and pKd of 8.73 and 9.3, respectively.
DESCRIPTION Pimavanserin (ACP-103)(ACP-103) is an effective and specific 5-HT2A receptor inverse agonist (mean pIC50: 8.7, in the cell-based functional assay). Pimavanserin is an atypical antipsychotic used in the treatment of hallucinations and psychosis in patients with Parkinson disease. (TargetMol Bioactive Compound Library)
DESCRIPTION Pimavanserin tartrate is a potent 5-HT 2A receptor inverse agonist used to treat Parkinson's disease-related psychosis, with the most potent inhibitory activity on the NFAT signaling pathway. (TargetMol Bioactive Compound Library)
Compound Sets
24
AdooQ Bioactive Compound Library
A14434
Cayman Chemical Bioactives
23462
ChEMBL Approved Drugs
CHEMBL2111101
CHEMBL2448613
ChEMBL Drugs
CHEMBL2111101
CHEMBL2448613
Concise Guide to Pharmacology 2017/18
8423
Concise Guide to Pharmacology 2019/20
8423
Concise Guide to Pharmacology 2021/22
8423
Concise Guide to Pharmacology 2023/24
8423
Drug Repurposing Hub
DrugBank
DB05316
DrugBank Approved Drugs
DB05316
DrugCentral
5142
DrugCentral Approved Drugs
5142
DrugMAP
DMR7IVC
DMOJA5G
DrugMAP Approved Drugs
DMR7IVC
EUbOPEN Chemogenomics Library
EUB0000784
Guide to Pharmacology
8423
MedChem Express Bioactive Compound Library
HY-14557
NCATS Inxight Approved Drugs
JZ963P0DIK
Novartis Chemogenetic Library (NIBR MoA Box)
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
pimavanserin
TargetMol Bioactive Compound Library
T2076
T6946
External IDs
56
Properties
(calculated by RDKit )
Molecular Weight
427.26
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
2
cLogP
4.67
TPSA
44.81
Fraction CSP3
0.48
Chiral centers
0.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
5-HT Receptor
5-HT2A
DRD2, HTR2A
MOA
5-HT Receptor inhibitor
SELECTIVE inverse agonist on the serotonin receptor subtype 5-HT2A
HTR2A (5HT2A) inverse agonist
"SELECTIVE inverse agonist on the serotonin receptor subtype 5-HT2A
HTR2A (5HT2A) inverse agonist"
serotonin receptor inverse agonist
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Member status
virtual
Indication
Parkinson's Disease
Recommended Cell Concentration
100 nM
Source data